A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer

Clin Genitourin Cancer. 2005 Dec;4(3):215-8. doi: 10.3816/CGC.2005.n.036.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Acid Phosphatase
  • Adenocarcinoma / immunology
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Adjuvants, Immunologic / therapeutic use
  • CD8-Positive T-Lymphocytes / immunology
  • Granulocyte-Macrophage Colony-Stimulating Factor / immunology
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • Humans
  • Interferon-alpha / biosynthesis
  • Male
  • Neoplasm Staging
  • Prostatic Neoplasms / immunology
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Protein Tyrosine Phosphatases / antagonists & inhibitors*
  • Treatment Outcome
  • Vaccines, DNA / immunology
  • Vaccines, DNA / therapeutic use*

Substances

  • Adjuvants, Immunologic
  • Interferon-alpha
  • Vaccines, DNA
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Acid Phosphatase
  • prostatic acid phosphatase
  • Protein Tyrosine Phosphatases